Time Flies Like a Song—Thank You for Being There | Guorui Yinuo’s 2024 Year-End Review
Release time:
2025-01-02 14:00
Keywords:
Medication,Trade
The heavens and earth are vast and boundless, while time slips away in a fleeting moment.
Looking back on 2024,
Those that are proud and inspiring. of the sudden Break and achievement,
Seemingly light and casual, just a few brief words,
Behind it all lie countless nights spent burning the midnight oil and drenched in sweat.
Time is the witness of development, and practice is the driving force behind it.
Standing at the end of the year, let’s take a moment to look back on Guorui Yinuo’s development journey in 2024.
01
Key data
The contract value for 2024 increased by approximately 10% compared to the previous year; 15 new customers were added in 2024.
Four new authorized patents were granted; two new patent applications were accepted.
02
Business Development
New drug delivery technology:
Subarachnoid administration (rabbit);
Epidural administration (rabbit);
Anterior chamber perfusion administration (rabbit);
Intracardiac administration (rabbit);
Urethral administration (rabbit);
Vaginal administration (rabbit);
Buccal administration via contact (golden hamster);
Nasal administration (rabbit).
New business scope:
Single-dose and repeated-dose toxicity studies (rodents);
Single-dose and repeated-dose toxicity studies (non-rodent, excluding primates);
Toxicokinetic studies;
Field trials for efficacy evaluation of pet medications;
Pet species bioequivalence studies;
Pharmacokinetic studies in pets;
Safety testing of target animals in the pet category;
Pharmacological efficacy evaluation tests for pets.
03
Honorary Qualifications
Passed the National Veterinary Drug GCP Certification by the Ministry of Agriculture and Rural Affairs in December 2023.
In July 2024, the facility passed the renewal and new application inspections for drug GLP conducted by the National Medical Products Administration (NMPA).
Guo Rui Yinuo received an “Excellent” rating in the 2024 Toxicological Pathomorphology Proficiency Testing Program.
Guo Rui Yinuo received satisfactory results in all evaluations during the 2024 clinical laboratory testing proficiency testing program.
In December 2023, it was recognized by the Xi'an Science and Technology Bureau as a “Xi'an New R&D Institution.”
In July 2024, it was recognized by the Shaanxi Provincial Department of Science and Technology as a “New Type of R&D Institution in Shaanxi Province.”
04
Undertake government research projects
In January 2024, undertook the Shaanxi Provincial Department of Science and Technology’s Qin Chuang Yuan “Scientists + Engineers” Team Building—Research on Key Common Technologies for Pharmacological Evaluation of Inhalation Drugs—“Scientists + Engineers” Team (Project No.: 2024QCY-KXJ-058).
05
Strengthen the enterprise through talent, and unleash motivation.
As of now, Guorui has a total of 67 employees, including 2 with doctoral degrees, 18 with master’s degrees, and 32 with bachelor’s degrees. In 2024, the company was recognized by the Shaanxi Provincial Department of Science and Technology as part of the Qin Chuangyuan “Scientists + Engineers” team. Additionally, Guorui has added one new Class C high-level talent in Xi'an and one young innovative talent under the Xi'an Talent Program.
With valleys and hills in our hearts, our brows and eyes become mountains and rivers.
2024 From lowlands to highlands,
Every leap forward is a rise.
The further we go in 2025, the more we must set our sights high and aim for great heights.
The farther we go through countless mountains and rivers, the stronger our aspirations must be, as firm as mountains themselves.
Dreams are distant, but if you pursue them, you can reach them.
Though the path may be arduous, persistence will lead to fulfillment.
Guorei Yinuo will continue to strengthen the construction and management of its safety assessment institutions, conducting non-clinical safety evaluation studies for drugs strictly in accordance with GLP requirements. This will effectively help companies shorten their new drug development cycles, enabling faster and safer drug launches! Guorei Yinuo will always uphold the philosophy of “human health and environmental safety,” providing high-quality services to customers worldwide.
About Guorui Yinuo
Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd. was established in November 2018. It is an independent, third-party drug safety evaluation research institution located in the Free Trade Pilot Zone of the Airport New City. In July 2021, Guorui Yinuo obtained the National Medical Products Administration’s Drug GLP (Good Laboratory Practice for Non-Clinical Studies) certification, becoming the first non-clinical drug safety research institution in the province to pass the national Drug GLP certification. This fills a gap in GLP laboratories in our province and will establish a convenient, efficient, and reliable technical platform for new drug development and preclinical safety evaluation in Shaanxi Province’s pharmaceutical industry. It will play a significant role in further enhancing Shaanxi Province’s drug R&D capabilities, its pharmaceutical industry’s independent innovation capacity, and the quality of drug research. As an important intermediate link in the transformation of innovative drugs from the innovation chain to the industrial chain, drug safety evaluation research supports the interaction and integration between the innovation chain and the industrial chain in the life sciences field under the “Qinchuangyuan” initiative, making it of great value to the development of the province’s life sciences industry. Currently, Guorui Yinuo has passed the veterinary drug GLP and GCP inspections conducted by the Ministry of Agriculture and Rural Affairs of China, as well as the CNAS GLP certification issued by the China National Accreditation Service for Conformity Assessment.
Guo Rui Yinuo has been recognized by the Xi'an Municipal Bureau of Industry and Information Technology as an innovative small and medium-sized enterprise in Shaanxi Province for 2022; by the Xi'an Municipal Science and Technology Bureau as the Engineering Technology Research Center for the “Non-clinical Safety Evaluation Research Platform for Pharmaceuticals” in Xi'an for 2022; by the Xi'an Municipal Science and Technology Bureau as a “New R&D Institution in Xi'an” for 2023; and by the Shaanxi Provincial Department of Science and Technology as a “New R&D Institution in Shaanxi Province” for 2024. Currently, Guo Rui Yinuo has one high-end innovation team under the Xixian New Area Qin Chuangyuan Innovation Talent Program, one “Scientists + Engineers” team under the Shaanxi Provincial Department of Science and Technology’s Qin Chuangyuan Initiative, three high-level talents (local leading talents) at the Xi'an municipal level, and three outstanding/D-category talents at the regional level.
Guorei Yinuo integrates drug toxicology, pathology, pharmacology, analytical testing, cosmetics, and bioequivalence evaluation services for generic drugs, possessing tremendous growth potential. The company’s building covers an area of 6,400 square meters, with Phase I investment exceeding 30 million yuan. Currently, it is equipped with over 300 pieces of advanced instrumentation, including liquid chromatography-mass spectrometry systems, high-performance liquid chromatographs, fully automated chemiluminescence immunoassay analyzers, animal blood analyzers, automatic tissue dehydrators, ultra-high-precision balances capable of measuring to one-millionth of a gram, animal oral and nasal inhalation exposure systems, UV-visible spectrophotometers, and fluorescence microscopes. The company has established experimental platforms covering genetic toxicology, analytical testing, reproductive toxicology, and clinical pathology. Dedicated to non-clinical safety evaluation of pharmaceuticals, we offer clients a one-stop service encompassing personalized protocol design, drug screening, pharmacodynamic studies, pharmacokinetic studies, safety assessments, and clinical trial sample analysis. We also provide safety evaluation services for food, health supplements, chemicals, and cosmetics. In addition, our company has set up platforms for the development of disease model animals and the breeding of laboratory animals. We have assembled a stable, experienced, and highly qualified professional team and have established a GLP-compliant system that simultaneously meets the regulatory requirements of the U.S. FDA, OECD, and China’s NMPA.
Related News
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681